# Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

> **NCT04887948** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 570 (actual)

## Conditions studied

- Pneumococcal Disease
- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine (20vPnC)
- **BIOLOGICAL:** BNT162b2
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT04887948
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2021-12-08
- **Final completion:** 2021-12-08
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887948, "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04887948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*